Get the Stockscreener App
5.63
2.93%
0.16
Pre-market:
5.83
0.20
+3.55%
Vir Biotechnology Inc stock is traded at $5.63, with a volume of 1.26M.
It is up +2.93% in the last 24 hours and down -1.57% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$5.47
Open:
$5.36
24h Volume:
1.26M
Relative Volume:
0.88
Market Cap:
$782.10M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.4362
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+9.75%
1M Performance:
-1.57%
6M Performance:
+25.11%
1Y Performance:
-34.84%
1-Day Range:
$5.36
$5.86
1-Week Range:
$5.22
$5.86
52-Week Range:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.63 | 761.01M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
How to manage a losing position in Vir Biotechnology Inc.2025 Risk Factors & AI Based Buy and Sell Signals - newser.com
Why Vir Biotechnology Inc. stock is favored by top institutionsRate Cut & Consistent Growth Stock Picks - newser.com
Is it too late to sell Vir Biotechnology Inc.2025 Trading Volume Trends & Daily Chart Pattern Signal Reports - newser.com
How Vir Biotechnology Inc. stock reacts to job market dataWeekly Risk Summary & Growth Focused Stock Pick Reports - newser.com
What to do if you’re stuck in Vir Biotechnology Inc.Trade Risk Summary & Daily Technical Forecast Reports - newser.com
Will Vir Biotechnology Inc. stock deliver consistent dividendsJuly 2025 Big Picture & Technical Buy Zone Confirmations - newser.com
What analysts say about Vir Biotechnology Inc stockSupport Zone Identification & Rapid Portfolio Trading - earlytimes.in
Vir Biotechnology Inc. stock trendline breakdown2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Can technical indicators confirm Vir Biotechnology Inc.’s reversalRisk Management & Free Community Consensus Stock Picks - newser.com
Visualizing Vir Biotechnology Inc. stock with heatmapsJuly 2025 Closing Moves & Real-Time Buy Zone Alerts - newser.com
How to escape a deep drawdown in Vir Biotechnology Inc.Market Sentiment Review & Risk Controlled Daily Trade Plans - newser.com
How Vir Biotechnology Inc. stock reacts to oil pricesQuarterly Performance Summary & Precise Swing Trade Alerts - newser.com
What the charts say about Vir Biotechnology Inc. todayWeekly Profit Analysis & Community Verified Watchlist Alerts - newser.com
Best data tools to analyze Vir Biotechnology Inc. stock2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Is Vir Biotechnology Inc. forming a reversal patternMarket Risk Analysis & High Return Stock Watch Alerts - newser.com
Published on: 2025-11-13 12:49:36 - newser.com
Tools to monitor Vir Biotechnology Inc. recovery probabilityTrade Volume Report & Real-Time Buy Signal Alerts - newser.com
How Vir Biotechnology Inc. stock reacts to inflationary pressuresMarket Risk Summary & Entry Point Confirmation Alerts - newser.com
Why Vir Biotechnology Inc. stock remains on watchlistsJuly 2025 Sector Moves & Verified Swing Trading Watchlists - newser.com
Vir Biotechnology advances hepatitis delta treatment, eyes unmet patient needs - Traders Union
Is now a turning point for Vir Biotechnology Inc.Quarterly Earnings Report & Weekly Market Pulse Updates - newser.com
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety - Quantisnow
Some Analysts Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates - simplywall.st
Vir Biotechnology (NASDAQ: VIR) Updates and S&P 500 Trends in Healthcare Sector - Kalkine Media
The Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Have Been Trimming Their Sales Forecasts - Yahoo Finance
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vir Biotechnology, Inc. Announces AASLD The Liver Meeting®? Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable S - MarketScreener
Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown - MSN
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):